

**ondine**



**For Immediate Release**

## **Ondine Biopharma Announces Management and Board Changes**

**VANCOUVER, BC, January 7, 2009**– Ondine Biopharma Corporation (the “Company” or “Ondine”, TSX: OBP; AIM: OBP) announces a reorganization to its senior management team reflecting the Company’s focus on the development of its photodisinfection product pipeline. Dr. Cale Street has been appointed Vice-President of Research of Ondine’s wholly-owned subsidiary, Ondine Research Laboratories, Inc. (“ORL”); located at the Company’s research facilities in Bothell, Washington. Mr. Thomas Dawson, who continues as an officer of ORL, has been appointed Chief Operating Officer of the Company. Dr. Nicolas Loebel, who continues as an officer of ORL and as Chief Technology Officer of the Company, has been appointed President of the Company.

Carolyn Cross, who continues to hold the title of Chief Executive Officer of the Company, has been appointed Chairman of Ondine’s Board of Directors, replacing Mr. Pierre Leduc who has resigned his positions of Executive Chairman and a Director of the Company effective January 6, 2009. Ondine wishes to thank Mr. Leduc for his contributions to the Company over the past 4 years and wishes him every success in his future endeavours.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

### **FOR FURTHER INFORMATION please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
ccross@ondinebiopharma.com

Adam Peeler  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 225  
apeeler@equicomgroup.com

Canaccord Adams Ltd  
Nominated Adviser & Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500